Overview

Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse

Status:
Completed
Trial end date:
1999-12-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Monoclonal antibody combined with a radioactive substance and given prior to bone marrow transplantation may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of radiolabeled monoclonal antibody given prior to bone marrow transplantation in treating patients with acute myelogenous leukemia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Treatments:
Antibodies
Busulfan
Cyclophosphamide
Methotrexate
Criteria
DISEASE CHARACTERISTICS: Acute myelogenous leukemia in first or second remission or
untreated first relapse Documented CD45 expression by leukemic cells required for patients
in relapse Phenotyping not required for patients in remission; such patients may have
leukemia previously documented to be CD45 negative Circulating blast count less than 10,000
(control with hydroxyurea or similar agent allowed) Genotypically or phenotypically
HLA-matched related marrow donor required No donors mismatched for 1 or more HLA antigens
No psychologic, physiologic, or medical contraindication to donation No high risk for
anesthesia because of age or medical problems No HIV seropositive donors

PATIENT CHARACTERISTICS: Age: 16 to 55 Performance status: Not specified Life expectancy:
Greater than 60 days Hematopoietic: Not applicable Hepatic: Bilirubin less than 1.5 mg/dl
No risk of developing veno-occlusive disease of the liver (i.e., current evidence of
hepatitis as manifested by SGOT greater than 1.5 x ULN) Renal: Creatinine less than 2.0
mg/dl Other: No HIV seropositivity No major infection

PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior radiotherapy to maximally
tolerated levels for any normal organ